Belite Bio, Inc.

BLTE Nasdaq SEC CIK 1889109
Follow Belite Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$77.6M
FY24−$36.1M
FY23−$31.6M
FY22−$12.6M
FY21−$9.7M
FY20−$5.8M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$37.1M
FY24−$29.4M
FY23−$29.9M
FY22−$11.9M
FY21−$7.5M
FY20-
FY19-